Small Pharma Analyst
Growth, long/short equity, biotech, healthcare

Cempra - Don't Throw The Baby Out With The Bathwater

Over the past month, every time I hear or read an article about the biotech pullback, I hear the same advice over and over - buy the large biotechs with earnings and stay away from small biotech with no marketed products. The same "safe" names come up repeatedly: Gilead, Biogen, Celgene, Amgen. Don't get me wrong, these are exceptional companies and their shares do look attractive, but this is not an article about making a bull or bear case for these large biotechs. Instead, let's focus on the small biotechs, some with no products and no earnings. The share price of many of these companies have been crushed as the change in sentiment has hit this sector doubly hard: the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details